Cancer Monoclonal Antibodies Market to reach $106.8 billion by 2031 | 7% CAGR

The Global Cancer monoclonal antibodies market size was valued at $55.6 billion in 2021, and is projected to reach $106.8 billion by 2031, growing at a CAGR of 7% from 2022 to 2031.

Cancer monoclonal antibodies (mAbs) are a type of immunotherapy that target cancer cells by binding to specific proteins on their surface. They are used for the treatment of various types of cancer, including breast cancer, lung cancer, and lymphoma. The global cancer monoclonal antibodies market is expected to grow significantly in the coming years, driven by the increasing prevalence of cancer, the rise in research and development activities, and the increasing demand for targeted therapies.

By application, the market is segmented into breast cancer, lung cancer, colorectal cancer, leukemia, lymphoma, and others. The breast cancer segment is expected to hold the largest market share due to the high prevalence of breast cancer and the increasing use of targeted therapies for its treatment.

𝐑𝐞𝐪𝐮𝐞𝐬𝐭 𝐚 𝐒𝐚𝐦𝐩𝐥𝐞 𝐂𝐨𝐩𝐲 𝐨𝐟 𝐭𝐡𝐞 𝐑𝐞𝐩𝐨𝐫𝐭: https://www.alliedmarketresearch.com/request-sample/32341

By type, the market is segmented into naked monoclonal antibodies, conjugated monoclonal antibodies, and bispecific monoclonal antibodies. The conjugated monoclonal antibodies segment is expected to hold the largest market share due to the increasing use of antibody-drug conjugates (ADCs) for cancer treatment.

By end-user, the market is segmented into hospitals, clinics, and others. The hospitals segment is expected to hold the largest market share due to the availability of advanced healthcare infrastructure and the increasing demand for innovative cancer therapies.

North America is expected to dominate the cancer monoclonal antibodies market due to the presence of a large number of pharmaceutical companies, high R&D investment, and supportive government initiatives. Europe and Asia-Pacific are also expected to witness significant growth during the forecast period.

𝐖𝐡𝐚𝐭 𝐢𝐬 𝐭𝐡𝐞 𝐈𝐦𝐩𝐚𝐜𝐭 𝐨𝐟 𝐂𝐨𝐯𝐢𝐝-𝟏𝟗 𝐏𝐚𝐧𝐝𝐞𝐦𝐢𝐜 𝐨𝐧 𝐂𝐚𝐧𝐜𝐞𝐫 𝐌𝐨𝐧𝐨𝐜𝐥𝐨𝐧𝐚𝐥 𝐀𝐧𝐭𝐢𝐛𝐨𝐝𝐢𝐞𝐬 𝐌𝐚𝐫𝐤𝐞𝐭 𝐆𝐥𝐨𝐛𝐚𝐥𝐥𝐲?

The outbreak of the COVID-19 pandemic had a negative impact on the cancer monoclonal antibodies market as the hospitalization rate for infected patients increased and the scope of hospitalization for patients for surgeries reduced significantly.

Due to the increase in hospitalization of Covid-19 patients, healthcare professionals postponed cancer treatments as patients with cancer have low immunity and there are high chances that they may catch infection quickly. Hence, the focus shifted to the management and control of the COVID-19 patients. Therefore, there was a reduction in cancer diagnosis cases during the pandemic, leading to a decline in demand for cancer monoclonal antibody testing.

The market has gained momentum with life getting back to normal.

𝐏𝐫𝐨𝐜𝐮𝐫𝐞 𝐂𝐨𝐦𝐩𝐥𝐞𝐭𝐞 𝐑𝐞𝐩𝐨𝐫𝐭 (𝟐𝟎𝟎 𝐏𝐚𝐠𝐞𝐬 𝐏𝐃𝐅 𝐰𝐢𝐭𝐡 𝐈𝐧𝐬𝐢𝐠𝐡𝐭𝐬, 𝐂𝐡𝐚𝐫𝐭𝐬, 𝐓𝐚𝐛𝐥𝐞𝐬,𝐅𝐢𝐠𝐮𝐫𝐞𝐬) https://www.alliedmarketresearch.com/checkout-final/fd3b82369f90375987256ab96c54d8eb

The report offers a detailed segmentation of the global cancer monoclonal antibodies market based on antibody type, application, end user, and region. The report provides an analysis of each segment and sub-segment with the help of tables and figures. This analysis helps market players, investors, and new entrants in determining the sub-segments to be tapped on to achieve growth in the coming years.

In terms of antibody type, the humanized segment captured the largest market share of two-fifths of the global cancer monoclonal antibodies market in 2021 and is expected to maintain a prominent revenue growth in 2031. The same segment is expected to achieve the fastest CAGR of 7.1% through 2031. The report also discusses the murine and chimeric segments.

In terms of application, the blood cancer segment captured the largest market share of more than one-third of the global cancer monoclonal antibodies market in 2021 and is likely to dominate the market in 2031. However, the lung cancer segment is expected to dominate in terms of revenue and achieve the fastest CAGR of 7.3% through 2031. The report also offers an analysis of breast cancer and others segments.

𝐅𝐨𝐫 𝐏𝐮𝐫𝐜𝐡𝐚𝐬𝐞 𝐈𝐧𝐪𝐮𝐢𝐫𝐲- https://www.alliedmarketresearch.com/purchase-enquiry/32341

Based on end user, the hospitals and clinics segment held the largest share in 2021, accounting for nearly three-fourths of the global cancer monoclonal antibodies market and would maintain its dominance through 2031. Moreover, the same segment is estimated to witness the fastest CAGR of 7.1% during the forecast period. The study also includes an analysis of the research and academic institute/laboratories segment.

Based on region, the market in North America was the largest in 2021, accounting for more than two-fifths of the global cancer monoclonal antibodies market in 2021 and is expected to rule the roost during the forecast period. However, the market in Asia-Pacific is expected to manifest the highest CAGR of 7.5% from 2022 to 2031. The other regions analyzed in the study include LAMEA and Europe.

𝐋𝐞𝐚𝐝𝐢𝐧𝐠 𝐩𝐥𝐚𝐲𝐞𝐫𝐬 𝐨𝐟 𝐭𝐡𝐞 𝐠𝐥𝐨𝐛𝐚𝐥 𝐜𝐚𝐧𝐜𝐞𝐫 𝐦𝐨𝐧𝐨𝐜𝐥𝐨𝐧𝐚𝐥 𝐚𝐧𝐭𝐢𝐛𝐨𝐝𝐢𝐞𝐬 𝐦𝐚𝐫𝐤𝐞𝐭 𝐚𝐧𝐚𝐥𝐲𝐳𝐞𝐝 𝐢𝐧 𝐭𝐡𝐞 𝐫𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐢𝐧𝐜𝐥𝐮𝐝𝐞,

Roche Holdings Ltd.
Johnson & Johnson
Pfizer Inc.
Novartis AG
AstraZeneca plc
Merck & Co. Inc.
Celgene Limited
Bistrol-Myers Squibb
Eli Lilly & Co.
Abbvie Inc.

𝐓𝐫𝐞𝐧𝐝𝐢𝐧𝐠 𝐑𝐞𝐩𝐨𝐫𝐭𝐬 𝐢𝐧 𝐇𝐞𝐚𝐥𝐭𝐡𝐜𝐚𝐫𝐞 𝐈𝐧𝐝𝐮𝐬𝐭𝐫𝐲:

Infertility Treatment Market Share : https://www.alliedmarketresearch.com/infertility-treatment-market-A09505

Branded Generics Market Size : https://www.alliedmarketresearch.com/branded-generics-market-A10537

𝐂𝐨𝐧𝐭𝐚𝐜𝐭:

David Correa
5933 NE Win Sivers Drive
205, Portland, OR 97220
United States
Toll Free: +1-800-792-5285
UK: +44-845-528-1300
Hong Kong: +852-301-84916
help@alliedmarketresearch.com
Web: https://www.alliedmarketresearch.com

𝐀𝐛𝐨𝐮𝐭 𝐀𝐥𝐥𝐢𝐞𝐝 𝐌𝐚𝐫𝐤𝐞𝐭 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡:

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting.

Allied Market Research CEO Pawan Kumar is instrumental in inspiring and encouraging everyone associated with the company to maintain high quality of data and help clients in every way possible to achieve success. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

This release was published on openPR.